Zobrazeno 1 - 10
of 26
pro vyhledávání: '"J C, Fleishaker"'
Autor:
P. Duchene, M. G. Jannuzzo, J. P. Laneury, Georges Houin, J. C. Fleishaker, P. Rampal, A. Tran
Publikováno v:
Clinical Drug Investigation. 19:473-477
Objective: Reboxetine is a unique selective norepinephrine (noradrenaline) reuptake inhibitor (selective NRI) that is effective and well tolerated at a dosage of 8 to 10 mg/day in the short- and long-term treatment of depression. The objective of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f99feb687e311a8cf519496ba85563db
https://doi.org/10.2165/00044011-200019060-00010
https://doi.org/10.2165/00044011-200019060-00010
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 38:254-259
Objectives: To examine the pharmacokinetic characteristics of the selective norepinephrine reuptake inhibitor, reboxetine, in elderly patients with depression. Patients: Twelve female inpatients (mean age 80 ± 4 years) with major depressive or dysth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c12eaff829638ac86f8556634bc6faa
https://doi.org/10.5414/cpp38254
https://doi.org/10.5414/cpp38254
Publikováno v:
Biopharmaceutics & Drug Disposition. 11:715-727
Food effects on adinazolam absorption from sustained release (SR) adinazolam mesylate tablets were assessed in 28 healthy male volunteers. Subjects received 15 mg SR tablets, 15 mg immediate release tablets, 15 mg oral solution, administered after an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d0e532234eff1c32c61c29660b9634a
https://doi.org/10.1002/bdd.2510110807
https://doi.org/10.1002/bdd.2510110807
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 25(3-4)
The pharmacokinetic characteristics of reboxetine, a unique selective noradrenaline reuptake inhibitor (selective NRI) for the treatment of depression, were studied in 12 healthy, elderly volunteers (mean age 81 years +/- 9 years). All subjects recei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0205f2a5a27709568296e779c99eb5af
https://pubmed.ncbi.nlm.nih.gov/11420889
https://pubmed.ncbi.nlm.nih.gov/11420889
Publikováno v:
British journal of clinical pharmacology. 51(5)
To assess the effect of a reversible MAO-A inhibitor, moclobemide, on the single-dose pharmacokinetics of almotriptan and assess the clinical consequences of any interaction.Twelve healthy volunteers received the following treatments in a randomized,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7428e0fd71bc1c5922231d03723b65b4
https://pubmed.ncbi.nlm.nih.gov/11422001
https://pubmed.ncbi.nlm.nih.gov/11422001
Publikováno v:
Clinical pharmacology and therapeutics. 66(4)
Ketoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme. Reboxetine, a selective norepinephrine reuptake inhibitor, is metabolized by cytochrome P450 3A4. The potential interaction of reboxetine with this representative from the azole de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::76a59e168f21da51a76815b811cacc99
https://pubmed.ncbi.nlm.nih.gov/10546921
https://pubmed.ncbi.nlm.nih.gov/10546921
Publikováno v:
Pharmaceutical research. 16(4)
Data collected during Phase I and II in the development of tirilazad were pooled and analyzed using nonlinear mixed effects models to assess covariates which might affect tirilazad pharmacokinetics.Four single dose and five multiple dose studies in n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::683d4b4aabba1bfcc4632197960327f0
https://pubmed.ncbi.nlm.nih.gov/10227715
https://pubmed.ncbi.nlm.nih.gov/10227715
Publikováno v:
Biopharmaceuticsdrug disposition. 20(1)
The absolute bioavailability of reboxetine enantiomers was assessed in six male and six female volunteers. In a two-way crossover study, subjects received 1.0 mg reboxetine orally and 0.3 mg reboxetine as an intravenous bolus. The R,R(-) and S,S(+) e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1c2484d092c00f48225953d41175868b
https://pubmed.ncbi.nlm.nih.gov/10086838
https://pubmed.ncbi.nlm.nih.gov/10086838
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 287(2)
Tirilazad mesylate (FREEDOX), a potent inhibitor of membrane lipid peroxidation in vitro, is under clinical development for the treatment of subarachnoid hemorrhage. In humans, tirilazad is cleared almost exclusively via hepatic elimination with a me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e16171bfc400b06084b4bee4bba1c0ba
https://pubmed.ncbi.nlm.nih.gov/9808684
https://pubmed.ncbi.nlm.nih.gov/9808684
Publikováno v:
Biopharmaceuticsdrug disposition. 19(2)
Tirilazad is a membrane lipid peroxidation inhibitor being studied for the management of subarachnoid hemorrhage; phenytoin is used for seizure prophylaxis in the same disorder. The induction of tirilazad clearance by phenytoin was assessed in 12 vol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f64c1993d8da5a9f3aeaccd6189fd121
https://pubmed.ncbi.nlm.nih.gov/9533108
https://pubmed.ncbi.nlm.nih.gov/9533108